| Literature DB >> 25533812 |
Yaghoub Safdari1, Masoumeh Khalili2, Mohammad Ali Ebrahimzadeh3, Yaghoub Yazdani4, Safar Farajnia5.
Abstract
Epidermal growth factor receptor (EGFR) plays a critical role in the initiation and progression of a variety of human cancers, including breast cancer. An important signaling pathway downstream of EGFR is the PI3K/AKt pathway, which regulates cellular processes as diverse as cell growth, survival, proliferation and migration. Deregulated activity of this pathway may lead to uncontrolled cell growth, survival, migration and invasion, contributing to tumor formation. In this review, we evaluate natural compounds that, in vitro (breast cancer cell lines) and/or in vivo (animal model, clinical) studies, suppress breast cancer cells or tumors mainly by suppressing the PI3K/AKT signaling pathway. The effect of these compounds on cell cycle arrest, inhibition of cell migration and invasion, tumor angiogenesis and metastasis in breast cancer are discussed.Entities:
Keywords: AKT; Ascofuranone (PubChem CID: 6434242); BYL-719 (PubChem CID: 56649450); Breast cancer; CDRI 85-287 (PubChem CID: 159508); Fenretinide: (PubChem CID: 5288209); Isoliquiritigenin (PubChem CID: 638278); Natural inhibitors; PI3K; Platycodin D (PubChem CID: 162859); Quercetin (PubChem CID: 5280343); Thymoquinone (PubChem CID:10281); Wogonin (PubChem CID: 5281703)
Mesh:
Substances:
Year: 2014 PMID: 25533812 DOI: 10.1016/j.phrs.2014.12.004
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658